0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Anti-Bleeding Gels - Global Strategic Business Report

  • PDF Icon

    Report

  • 383 Pages
  • June 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6094677
The global market for Anti-Bleeding Gels was estimated at US$5.9 Billion in 2024 and is projected to reach US$7.8 Billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Anti-Bleeding Gels market.

Global Anti-Bleeding Gels Market - Key Trends & Drivers Summarized

Why Are Anti-Bleeding Gels Gaining Momentum in Emergency and Surgical Medicine?

The increasing reliance on anti-bleeding gels in medical care represents a significant advancement in trauma and surgical response. Traditionally, controlling bleeding has involved a combination of gauze, sutures, and manual pressure, methods that can be time-consuming and often inadequate in severe or complex injuries. Anti-bleeding gels, by contrast, offer a fast-acting, highly effective alternative that can be applied directly to wounds to stem blood flow within seconds. These gels work by accelerating the body's natural clotting mechanisms, forming a stable barrier that halts bleeding and protects the site from further injury. Their use has become particularly prevalent in emergency medicine on battlefields, in ambulances, and during natural disasters where rapid blood loss can be fatal if not addressed immediately. Surgical teams have also adopted anti-bleeding gels to minimize intraoperative and postoperative blood loss, thereby reducing complications and the need for transfusions. The appeal lies in their versatility; they can be used in superficial cuts, deep lacerations, and internal surgical sites alike. In many cases, the gels reduce operation time and enhance patient recovery by creating a clean, sealed wound environment that supports healing. Their compact, easy-to-use packaging makes them ideal for field medics and first responders, while their sterile formulation ensures compatibility with operating room protocols. As healthcare professionals seek faster, more efficient methods to manage bleeding, these gels are transitioning from specialty items to staples in trauma kits, surgical packs, and home first-aid supplies, signifying a paradigm shift in how bleeding is managed in both controlled and uncontrolled environments.

How Are Advances in Bioengineering Enhancing the Performance of Anti-Bleeding Gels?

The efficacy and safety of anti-bleeding gels have been significantly elevated through breakthroughs in biomaterials science and biomedical engineering. Early formulations relied on basic polysaccharides and gel-based matrices, but modern versions have advanced to include bioactive agents that work synergistically with the body's natural hemostatic process. Many of today's anti-bleeding gels are composed of materials such as chitosan, collagen, oxidized cellulose, and synthetic polymers, each tailored for specific types of bleeding and tissue interaction. These substances not only encourage platelet aggregation but also create a physical seal that adheres firmly to wet tissues a crucial feature during active hemorrhage. The integration of clotting factors like thrombin and fibrinogen into gel matrices has further improved their coagulation speed and effectiveness. Additionally, some gels are now being developed with antimicrobial properties, combining bleeding control with infection prevention, especially valuable in high-risk or contaminated environments. Biodegradable and bioresorbable gels are also emerging, which dissolve naturally in the body over time and eliminate the need for removal, reducing patient discomfort and the risk of secondary complications. Innovations in nanoengineering have made it possible to produce gels with enhanced surface area, improved tissue adhesion, and faster reactivity, all of which contribute to more reliable and predictable results. Moreover, research is ongoing into smart gels that can respond to the severity of bleeding by adjusting their viscosity or releasing clotting agents in controlled doses. These technological advancements are not just improving outcomes in routine clinical settings but also making life-saving interventions possible in scenarios where conventional tools fall short, further expanding the global demand for this category of products.

Why Are Clinicians and Healthcare Institutions Rapidly Integrating Anti-Bleeding Gels Into Practice?

Healthcare institutions are increasingly integrating anti-bleeding gels into standard medical protocols due to the growing emphasis on patient safety, treatment efficiency, and surgical precision. In surgical procedures across specialties orthopedics, cardiovascular, dental, gynecology, and neurosurgery controlling bleeding is not only critical for visibility but also essential for reducing operation time and the risk of complications. Anti-bleeding gels provide a clean, quick solution to manage minor and moderate bleeds without the delay associated with traditional cauterization or suturing techniques. Their application is especially useful in minimally invasive procedures, where access to bleeding sites is limited, and traditional methods are impractical. Beyond the operating room, these gels are being used in outpatient and home care settings, providing clinicians with portable and efficient tools for treating bleeding wounds, ulcers, and even nosebleeds. In trauma units, gels are helping manage bleeding in patients with coagulation disorders, where clotting is otherwise impaired. Furthermore, their ease of use requires minimal training, making them an invaluable addition to emergency kits for paramedics, military medics, and disaster response teams. Hospitals and clinics are also responding to mounting pressure to reduce readmission rates and post-operative complications, and anti-bleeding gels play a role by minimizing the risks associated with prolonged bleeding or infection at surgical sites. The reduction in blood product usage, such as transfusions, also aligns with institutional cost-containment strategies and patient safety goals. With a rising number of procedures being performed on elderly and medically complex patients, clinicians are prioritizing techniques and tools that offer reliability, sterility, and speed needs that anti-bleeding gels are uniquely positioned to meet.

What Key Drivers Are Fueling the Global Market Growth of Anti-Bleeding Gels?

The growth in the anti-bleeding gels market is driven by several key factors related to healthcare trends, product innovation, and changing clinical practices. A major driver is the global increase in surgical procedures, especially elective and minimally invasive surgeries that require precise, localized hemostasis without excessive tissue trauma. Additionally, the surge in trauma cases due to traffic accidents, natural disasters, and armed conflicts is generating strong demand for portable, fast-acting bleeding control solutions. Another significant factor is the aging global population, which is more prone to chronic conditions, delayed healing, and coagulation disorders, creating a sustained need for advanced hemostatic interventions. Innovations in biocompatible and multifunctional gel formulations have broadened the range of medical settings in which these products can be used, from hospital ORs to outpatient clinics and even battlefield environments. The expanding adoption of anti-bleeding gels in dental surgeries, dermatological procedures, and sports medicine is also opening new revenue streams for manufacturers. Moreover, increasing awareness of the dangers associated with blood transfusions including infections, immune reactions, and supply shortages is pushing healthcare providers toward alternatives that reduce blood loss and dependence on donor blood. Favorable regulatory approvals, especially in North America and Europe, are speeding up the commercialization of new formulations. In emerging economies, where access to advanced surgical tools is limited, anti-bleeding gels offer a cost-effective and highly impactful solution, thus widening the market's geographic footprint. Strategic partnerships between biotech firms and medical distributors, along with growing investments in R&D, are further accelerating innovation and global penetration. Collectively, these factors are laying the foundation for sustained growth, making anti-bleeding gels an increasingly indispensable component of modern wound care and surgical practice.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Veterinary Use Anti-Bleeding Gel segment, which is expected to reach US$5.0 Billion by 2030 with a CAGR of a 5.7%. The Human Use Anti-Bleeding Gel segment is also set to grow at 3.3% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $1.6 Billion in 2024, and China, forecasted to grow at an impressive 8.9% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Anti-Bleeding Gels Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Anti-Bleeding Gels Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Anti-Bleeding Gels Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as 3M, Aesculap (B. Braun Melsungen), AngioDynamics, Aspen Surgical, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 44 companies featured in this Anti-Bleeding Gels market report include:

  • 3M
  • Aesculap (B. Braun Melsungen)
  • AngioDynamics
  • Aspen Surgical
  • Baxter International Inc.
  • Biom’up
  • Bioventus
  • Celgen
  • CryoLife, Inc.
  • DemeTECH Corporation
  • Johnson & Johnson (Ethicon)
  • Lincare Holdings
  • Medtronic
  • Omrix Biopharmaceuticals
  • Pharmascience Inc.
  • Porcine Biotech
  • Stryker Corporation
  • Terumo Corporation
  • Vericel Corporation
  • Zoetis

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Anti-Bleeding Gels - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Trauma and Surgical Procedures Throws the Spotlight on Anti-Bleeding Gels
  • Adoption in Emergency Medicine and Field Applications Spurs Demand for Rapid Hemostasis Solutions
  • Advances in Biopolymer-Based Gel Formulations Enhance Bio-Absorption and Wound Compatibility
  • Expansion of Dental, ENT, and Neurosurgery Use Cases Broadens Clinical Adoption
  • Integration of Antibacterial Agents With Hemostatic Function Strengthens Dual-Purpose Efficacy
  • OEM Innovation in Preloaded Applicators Improves Ease of Use in Surgical Settings
  • Increased Preference for Animal-Free and Plant-Based Gels Supports Broader Patient Acceptance
  • Growth in Outpatient Surgeries and Daycare Procedures Drives Demand for Quick Recovery Aids
  • OEM Focus on Reabsorbable, Non-Toxic Materials Enhances Post-Operative Safety Profiles
  • Use in Military, Sports Medicine, and Disaster Relief Enhances Field Utility
  • Rising Use in Robotic and Minimally Invasive Surgery Encourages Gel-Based Hemostasis
  • Advancements in Shelf-Stable, Single-Dose Formats Support Portability and Storage Efficiency
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anti-Bleeding Gels Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anti-Bleeding Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Anti-Bleeding Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Anti-Bleeding Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Veterinary Use Anti-Bleeding Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Veterinary Use Anti-Bleeding Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Veterinary Use Anti-Bleeding Gel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Human Use Anti-Bleeding Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Human Use Anti-Bleeding Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Human Use Anti-Bleeding Gel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Veterinary Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Veterinary Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Veterinary Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Retail Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Biopsies of Soft Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Biopsies of Soft Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Biopsies of Soft Tissue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Trauma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Enucleations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Enucleations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Enucleations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Orthopedic Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Orthopedic Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Orthopedic Surgeries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Anti-Bleeding Gels Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3M
  • Aesculap (B. Braun Melsungen)
  • AngioDynamics
  • Aspen Surgical
  • Baxter International Inc.
  • Biom’up
  • Bioventus
  • Celgen
  • CryoLife, Inc.
  • DemeTECH Corporation
  • Johnson & Johnson (Ethicon)
  • Lincare Holdings
  • Medtronic
  • Omrix Biopharmaceuticals
  • Pharmascience Inc.
  • Porcine Biotech
  • Stryker Corporation
  • Terumo Corporation
  • Vericel Corporation
  • Zoetis

Table Information

This website uses cookies to ensure you get the best experience. Learn more